Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab safety study in advanced NSCLC
NCT03090737Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jun 2017
- Primary completion
- Feb 2021
- Modality
- Monoclonal Antibodies
- Countries
- 5
01
Overview
A Phase 2 trial of nivolumab in non-small cell lung cancer (NSCLC), sponsored by Bristol Myers Squibb. Started Jun 2017; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03090737.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03090737.